BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 11590434)

  • 1. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
    Gorelik L; Flavell RA
    Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Better tumor eradication in transgenic altered T-lymphocytes. Role of the TGF-beta signal transduction cascade].
    Hautarzt; 2001 Dec; 52(12):1135-6. PubMed ID: 11910867
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
    Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
    Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-beta pathway serves as a primary tumor suppressor in CD8+ T cell tumorigenesis.
    Lucas PJ; McNeil N; Hilgenfeld E; Choudhury B; Kim SJ; Eckhaus MA; Ried T; Gress RE
    Cancer Res; 2004 Sep; 64(18):6524-9. PubMed ID: 15374963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
    Koehler H; Kofler D; Hombach A; Abken H
    Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
    Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
    J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta superfamily enhances the antigen-induced IFN-gamma production by effector/memory CD8+ T cells.
    Takai S; Tokuda H; Matsushima-Nishiwaki R; Saio M; Takami T; Kozawa O
    Int J Mol Med; 2010 Jan; 25(1):105-11. PubMed ID: 19956908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
    Zhong Z; Carroll KD; Policarpio D; Osborn C; Gregory M; Bassi R; Jimenez X; Prewett M; Liebisch G; Persaud K; Burtrum D; Wang S; Surguladze D; Ng S; Griffith H; Balderes P; Doody J; Schwartz JD; Youssoufian H; Rowinsky EK; Ludwig DL; Witte L; Zhu Z; Wu Y
    Clin Cancer Res; 2010 Feb; 16(4):1191-205. PubMed ID: 20145179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
    Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
    Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
    Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
    Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection.
    Martin DL; Postan M; Lucas P; Gress R; Tarleton RL
    Eur J Immunol; 2007 Oct; 37(10):2764-71. PubMed ID: 17823982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
    Kosiewicz MM; Alard P; Liang S; Clark SL
    Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.